Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605384 · ClinicalTrials.gov registry record · Phase 3
A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 3
- Development phase
- 4
- Enrollment target
NCT00605384 is a Phase 3 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 4 participants.
The verdict
NCT00605384, a Phase 3 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 4 participants
- Enrollment target
Study Summary
The purpose of this clinical research study is to find out whether a combination of entecavir (ETV) plus tenofovir (TNF) works better against Hepatitis B virus than adefovir (ADV) added to continuing lamivudine (LVD) therapy in patients whose Hepatitis B virus (HBV) is resistant against lamivudine. The safety of this treatment will also be studied.
Interventions
- DRUG Entecavir + Tenofovir
- DRUG Adefovir + continuing Lamivudine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2008-08 |
| Est. Completion | 2009-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605384
The ClinicalTrials.gov registry entry for NCT00605384 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Entecavir + Tenofovir is the first listed.
NCT00605384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605384 about?
NCT00605384 is a clinical study titled "A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection". The purpose of this clinical research study is to find out whether a combination of entecavir (ETV) plus tenofovir (TNF) works better against Hepatitis B virus than adefovir (ADV) added to continuing lamivudine (LVD) therapy in patients whose Hepatitis B virus (HBV) is resistant against lamivudine. ...
What is the current status of trial NCT00605384?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 4 participants. The study started on 2008-08. Estimated completion is 2009-02.
What interventions are being tested in trial NCT00605384?
The interventions under investigation include: Entecavir + Tenofovir (DRUG), Adefovir + continuing Lamivudine (DRUG).
Who is sponsoring clinical trial NCT00605384?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.